Exploring the Relationship between Periodontitis, Anti-Periodontitis Therapy, and Extra-Oral Cancer Risk: Findings from a Nationwide Population-Based Study

Abstract

This study aimed to evaluate the systemic impact of periodontitis, previously considered a local disease, on cancer occurrence. We enrolled 683,854 participants, comparing cancer incidence among those with and without periodontitis and assessing the impact of periodontal treatment on cancer risk. Regardless of gender, age, Charlson comorbidity index, or the use of non-steroidal anti-inflammatory drugs, periodontitis patients had a lower overall cancer risk than controls. However, men with periodontitis had a higher risk of prostate cancer (adjusted hazard ratio [aHR] = 1.22; 95% confidence interval [CI] = 1.10–1.35), and both men and women had a higher risk of thyroid cancer (women: aHR = 1.20, 95%CI = 1.04–1.38; men: aHR = 1.51, 95% CI = 1.15–1.99). Patients with periodontitis who received treatment showed a reduced cancer risk (aHR = 0.41; 95% CI = 0.38–0.44) compared to untreated patients. Proper treatment for periodontitis may lower an individual’s cancer risk more than if they did not have the disease at all, suggesting that periodontitis is a modifiable risk factor for cancer.

The Impact of Chronic Pancreatitis on the Occurrences of Human Cancers: Real-World Data

“…To identify patients with cancer, we employed the linked registry of the Registry for Catastrophic Illness Patient Database (RCIPD), also derived from the NHIRD in Taiwan. Disease diagnoses were categorized utilizing the International Classification of Diseases, Ninth and Tenth Revision, and Clinical Modification (ICD-9-CM and ICD-10-CM) coding systems, as previously described in our published works [14][15][16][17][18][19][20][21][22][23][24][25]. Ethical approval for this study was obtained from the Institutional Review Board of the China Medical University Hospital Research Ethics Committee (CMUH109-REC2-031(CR-2)).…”

“…The primary objective of this study was to investigate the occurrence of various types of primary cancer as the study outcome. The types of cancer were classified as follows: liver (ICD-9: 155, ICD-10: C22), breast (ICD-9: 174, ICD-10: C50.0, C50.1, C50.2, C50.3, C50.411, C50.412, C50.419), lung (ICD-9: 162, ICD-10: C33, C34, C7A.090), thyroid (ICD-9: 193, ICD-10: C73, E31.22), colon rectum (ICD-9: 153,154, ICD-10: C18, C19, C20, C21, C7A.02), prostate (ICD-9: 185, ICD-10: C61), kidney (ICD-9: 189, ICD-10: C64, C65, C66, C68, C7A.093), nasopharynx (ICD-9: 147, ICD-10: C11), stomach (ICD-9: 151, ICD-10: C16, C7A.092), bladder (ICD-9: 188, ICD-10: C67), and other cancers [18]. The covariates considered in the analysis included sex, age categories (20-39, 40-59, ≥60), CCI, and NSIADs, which were compared between subjects with and without CP.…”